New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension

OBJECTIVE: Tocilizumab plus prednisone induces sustained glucocorticoid-free remission in patients with GCA. However, its long-term benefits in new-onset vs relapsing disease are uncertain, and the value of weekly vs every-other-week dosing has not been evaluated. METHODS: In Giant-Cell Arteritis Ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Stone, John H, Spotswood, Helen, Unizony, Sebastian H, Aringer, Martin, Blockmans, Daniel , Brouwer, Elisabeth, Cid, Maria C, Dasgupta, Bhaskar, Rech, Juergen, Salvarani, Carlo, Spiera, Robert, Bao, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258533/
https://www.ncbi.nlm.nih.gov/pubmed/34718434
http://dx.doi.org/10.1093/rheumatology/keab780

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258533/
https://www.ncbi.nlm.nih.gov/pubmed/34718434
http://dx.doi.org/10.1093/rheumatology/keab780

Ejemplares similares